Tom Dymond
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
Papers in
-
- SARS-CoV-2 and COVID-19 Research 5
- SARS-CoV-2 detection and testing 2
- COVID-19 Clinical Research Studies 1
- Clostridium difficile and Clostridium perfringens research 1
-
- COVID-19 epidemiological studies 2
- Co-authors
- Pamela W. Ewan (1 shared paper)Shuaib M. Nasser (1 shared paper)Padmalal Gurugama (1 shared paper)Priya Sellaturay (1 shared paper)
- Journals
- The Lancet (6 papers)BMJ Open (1 paper)The Lancet Diabetes & Endocrinology (1 paper)The Lancet Infectious Diseases (1 paper)EClinicalMedicine (1 paper)
- Partner nations
- United KingdomAustraliaItaly
In The Last Decade
Tom Dymond
16 papers receiving 1.7k citations
Tom Dymond's Hit Papers
Peers
Comparison fields: 5 of 110
- Infectious Diseases 1.0k
- Applied Microbiology and Biotechnology 50
- Neurology 347
- Internal Medicine 56
- Obstetrics and Gynecology 86
Countries citing papers authored by Tom Dymond
This map shows the geographic impact of Tom Dymond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Dymond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Dymond more than expected).
Fields of papers citing papers by Tom Dymond
This network shows the impact of papers produced by Tom Dymond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Dymond. The network helps show where Tom Dymond may publish in the future.
Co-authors
The 4 scholars most cited alongside Tom Dymond, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2023 | 83 | |
| 7 | 2021 | 40 | |
| 8 | 2021 | 28 | |
| 9 | 2023 | 24 | |
| 10 | 2024 | 23 | |
| 11 | 2022 | 13 | |
| 12 | 2020 | 10 | |
| 13 | 2021 | 9 | |
| 14 | 2024 | 7 | |
| 15 | 2025 | 5 | |
| 16 | 2025 | 2 |
About Tom Dymond
Tom Dymond is a scholar working on Infectious Diseases, Modeling and Simulation, Nutrition and Dietetics, Oncology and Pulmonary and Respiratory Medicine, having authored 16 papers that have together received 1.8k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 epidemiological studies (2 papers), SARS-CoV-2 detection and testing (2 papers), Infection Control and Ventilation (1 paper), COVID-19 Clinical Research Studies (1 paper), Clostridium difficile and Clostridium perfringens research (1 paper), COVID-19 and healthcare impacts (1 paper) and Gut microbiota and health (1 paper). The work is most often cited by research in Infectious Diseases (1.0k citations), Applied Microbiology and Biotechnology (50 citations), Neurology (347 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (86 citations). Tom Dymond has collaborated with scholars based in United Kingdom, Australia and Italy. Frequent co-authors include Pamela W. Ewan, Shuaib M. Nasser, Padmalal Gurugama and Priya Sellaturay. Their work appears in journals such as The Lancet, BMJ Open, The Lancet Diabetes & Endocrinology, The Lancet Infectious Diseases and EClinicalMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.